[go: up one dir, main page]

WO1999024022A3 - Isoquinoline derivatives for treating disorders associated with 5ht7 receptors - Google Patents

Isoquinoline derivatives for treating disorders associated with 5ht7 receptors Download PDF

Info

Publication number
WO1999024022A3
WO1999024022A3 PCT/EP1998/006920 EP9806920W WO9924022A3 WO 1999024022 A3 WO1999024022 A3 WO 1999024022A3 EP 9806920 W EP9806920 W EP 9806920W WO 9924022 A3 WO9924022 A3 WO 9924022A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
isoquinoline derivatives
disorders associated
treating disorders
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/006920
Other languages
French (fr)
Other versions
WO1999024022A2 (en
Inventor
Thierry Godel
Walter Hunkeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to AU15588/99A priority Critical patent/AU1558899A/en
Publication of WO1999024022A2 publication Critical patent/WO1999024022A2/en
Publication of WO1999024022A3 publication Critical patent/WO1999024022A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of isoquinoline derivatives of general formula (I) wherein R?1, R2 and R3¿ are hydrogen, halogen, lower alkyl, lower alkoxy or R?2 and R3¿ taken together form a methylenedioxy group, Z is (a), (b), (c) or (d); R is CF¿3?, halogen, lower alkoxy, lower alkyl or lower alkyl-halogen; p is 1-3; n is 0-5 and of their pharmaceutically acceptable salts in the treatment of disorders which are associated with 5HT7 receptors.
PCT/EP1998/006920 1997-11-10 1998-11-02 Isoquinoline derivatives for treating disorders associated with 5ht7 receptors Ceased WO1999024022A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15588/99A AU1558899A (en) 1997-11-10 1998-11-02 Isoquinoline derivatives for use against cns disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97119650.6 1997-11-10
EP97119650 1997-11-10

Publications (2)

Publication Number Publication Date
WO1999024022A2 WO1999024022A2 (en) 1999-05-20
WO1999024022A3 true WO1999024022A3 (en) 1999-07-22

Family

ID=8227597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006920 Ceased WO1999024022A2 (en) 1997-11-10 1998-11-02 Isoquinoline derivatives for treating disorders associated with 5ht7 receptors

Country Status (4)

Country Link
AR (1) AR016005A1 (en)
AU (1) AU1558899A (en)
WO (1) WO1999024022A2 (en)
ZA (1) ZA9810218B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8883808B2 (en) 2005-08-04 2014-11-11 Janssen Pharmaceutica N.V. Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy
WO2024216197A3 (en) * 2023-04-13 2025-03-20 Acelot, Inc. Compounds and methods for treating protein aggregation diseases

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
US7928121B2 (en) 2002-02-19 2011-04-19 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP1676844A1 (en) 2004-12-28 2006-07-05 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
JP4399862B2 (en) * 2002-08-09 2010-01-20 味の素株式会社 Treatment for bowel disease and visceral pain
US7553965B2 (en) 2002-11-07 2009-06-30 Laboratories Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP1676840A1 (en) 2004-12-28 2006-07-05 Laboratorios Del Dr. Esteve, S.A. 5-HT7 Receptor antagonists
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7211585B2 (en) 2004-08-18 2007-05-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
US7211584B2 (en) 2004-08-18 2007-05-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor ligands
EP1630159A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP2149373A1 (en) 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. 5HT7 receptor ligands and compositions comprising the same
EP2151777A1 (en) 2008-08-01 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter
WO2012162814A1 (en) * 2011-06-01 2012-12-06 Mcmaster University Novel antibacterial combination therapy
US8883796B2 (en) 2013-02-08 2014-11-11 Korea Institute Of Science And Technology Biphenyl derivatives, pharmaceutical composition comprising the same, and preparation method thereof
US9663464B2 (en) 2015-02-24 2017-05-30 Korea Institute Of Science And Technology Carbazole derivatives acting on 5-HT7 receptor
CA3001484A1 (en) 2015-10-19 2017-04-27 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
WO2017190109A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
KR101917264B1 (en) 2016-12-22 2018-11-13 한국과학기술연구원 Azepine derivaties acting on 5-HT7 receptor ligand

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261998A (en) * 1978-05-18 1981-04-14 Synthelabo Tetrahydro-isoquinoline derivatives
US4963563A (en) * 1989-10-13 1990-10-16 Abbott Laboratories 6-substituted-1,2,3,4-tetrahydroisoquinolines
WO1997023458A1 (en) * 1995-12-22 1997-07-03 Warner-Lambert Company Subtype-selective nmda receptor ligands and the use thereof
WO1997041090A1 (en) * 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261998A (en) * 1978-05-18 1981-04-14 Synthelabo Tetrahydro-isoquinoline derivatives
US4963563A (en) * 1989-10-13 1990-10-16 Abbott Laboratories 6-substituted-1,2,3,4-tetrahydroisoquinolines
WO1997023458A1 (en) * 1995-12-22 1997-07-03 Warner-Lambert Company Subtype-selective nmda receptor ligands and the use thereof
WO1997041090A1 (en) * 1996-05-01 1997-11-06 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRAY, NANCY M. ET AL: "Phencyclidine-like effects of tetrahydroisoquinolines and related compounds", J. MED. CHEM. (1989), 32(6), 1242-8 CODEN: JMCMAR;ISSN: 0022-2623, XP000652263 *
MOKROSZ, JERZY L. ET AL: "Structure-activity relationship studies of CNS agents. Part 23. N-(3-phenylpropyl)- and N-[(E)-cinnamyl]-1,2,3,4-tetrahydroisoquinoline mimic 1-phenylpiperazine at 5-HT1A receptors", ARCH. PHARM. (WEINHEIM, GER.) (1995), 328(7-8), 604-8 CODEN: ARPMAS;ISSN: 0365-6233, XP002103486 *
REHSE, KLAUS ET AL: "Neuropsychotropic activity of dopamine-analogous piperidine and piperazin derivatives", ARCH. PHARM. (WEINHEIM, GER.) (1979), 312(8), 670-81 CODEN: ARPMAS;ISSN: 0365-6233, XP002103485 *
STAMBACH, J. F. ET AL: "2-(Aminobenzyl)-1,2,3,4-tetrahydroisoquinolines: a new class of.alpha.2-adrenergic receptor antagonists", EUR. J. MED. CHEM. (1993), 28(5), 427-32 CODEN: EJMCA5;ISSN: 0223-5234, XP002103487 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618288B2 (en) 2003-09-17 2013-12-31 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8883808B2 (en) 2005-08-04 2014-11-11 Janssen Pharmaceutica N.V. Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy
WO2024216197A3 (en) * 2023-04-13 2025-03-20 Acelot, Inc. Compounds and methods for treating protein aggregation diseases

Also Published As

Publication number Publication date
AR016005A1 (en) 2001-05-30
AU1558899A (en) 1999-05-31
WO1999024022A2 (en) 1999-05-20
ZA9810218B (en) 1999-05-10

Similar Documents

Publication Publication Date Title
WO1999024022A3 (en) Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
WO2001072728A3 (en) Novel piperazine derivatives
ES8707223A1 (en) Benzothiazole and benzothiophene derivatives.
ATE139233T1 (en) ANNELATED THIOPHENE DERIVATIVES, THEIR PREPARATION AND USE
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
WO1998035951A3 (en) New aminopiperazine derivatives
DK0579833T3 (en) Ethanolamine derivatives with anti-pollakisuria action
CA2207348A1 (en) Benzimidazole derivatives
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
WO1995001170A3 (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
EP0470686A3 (en) (benzhydryloxyethylpiperidyl)aliphatic acid derivatives and their use in the treatment of allergies and asthma
SE9702716D0 (en) Substituted phenylazacycloalkanes in the treatment of cognitive disorders
PT82550A (en) 1,3 oxathiane derivatives
AU1878297A (en) Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers
AP2002002595A0 (en) Heterocyclic amide derivatives.
NO973242L (en) Use of 3,4-diphenylchromanes for the preparation of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiological gynecomastia
MXPA98005355A (en) 5-[(heteroaryl) alkyl]-3 -oxo-pyrido [1, 2-a] benzimidazole -4-carboxamide derivatives useful in treating central nervous system disorders.
IE810992L (en) Benzodioxines
WO1999051591A3 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
PL347584A1 (en) Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA